Felix Grabherr
Overview
Explore the profile of Felix Grabherr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
1167
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Prosenz J, Grabherr F, Semmler G, Fickert P, Hofer H, Maieron A, et al.
Eur J Gastroenterol Hepatol
. 2025 Jan;
PMID: 39869490
Objective: We aimed to collect data on gastroenterology and hepatology training from the viewpoint of trainees and trainers. Methods: A national online survey was distributed among trainees and specialists at...
2.
Schwarzler J, Mayr L, Grabherr F, Tilg H, Adolph T
Trends Cell Biol
. 2024 Feb;
34(11):913-927.
PMID: 38341347
The gut epithelium protects the host from a potentially hostile environment while allowing nutrient uptake that is vital for the organism. To maintain this delicate task, the gut epithelium has...
3.
Effenberger M, Grander C, Grabherr F, Tilg H
J Clin Transl Hepatol
. 2024 Jan;
11(7):1498-1507.
PMID: 38161503
Nonalcoholic fatty liver disease (NAFLD) particularly affects patients with type 2 diabetes and obesity. The incidence of NAFLD has increased significantly over the last decades and is now pandemically across...
4.
Schwarzler J, Grabherr F, Grander C, Adolph T, Tilg H
Expert Rev Clin Immunol
. 2023 Dec;
20(4):375-386.
PMID: 38149354
Introduction: Metabolic-associated liver diseases have emerged pandemically across the globe and are clinically related to metabolic disorders such as obesity and type 2 diabetes. The new nomenclature and definition (i.e....
5.
Grander C, Meyer M, Steinacher D, Claudel T, Hausmann B, Pjevac P, et al.
JHEP Rep
. 2023 Oct;
5(11):100872.
PMID: 37818230
Background & Aims: Alcohol-related liver disease (ALD) is a global healthcare challenge with limited treatment options. 24-Norursodeoxycholic acid (NorUDCA) is a synthetic bile acid with anti-inflammatory properties in experimental and...
6.
Grander C, Grabherr F, Tilg H
Cardiovasc Res
. 2023 Jun;
119(9):1787-1798.
PMID: 37364164
The prevalence of non-alcoholic fatty liver disease (NAFLD) is continually increasing due to the global obesity epidemic. NAFLD comprises a systemic metabolic disease accompanied frequently by insulin resistance and hepatic...
7.
Effenberger M, Waschina S, Bronowski C, Sturm G, Tassiello O, Sommer F, et al.
Hepatol Commun
. 2023 Jun;
7(7).
PMID: 37314752
Background: HCC is the leading cause of cancer in chronic liver disease. A growing body of experimental mouse models supports the notion that gut-resident and liver-resident microbes control hepatic immune...
8.
Si J, Vazquez-Castellanos J, Gregory A, Decommer L, Rymenans L, Proost S, et al.
Nat Aging
. 2023 Apr;
2(10):885-895.
PMID: 37118287
Extensive scientific and clinical microbiome studies have explored contemporary variation and dynamics of the gut microbiome in human health and disease, yet the role of long-term life history effects has...
9.
Grabherr F, Grander C, Effenberger M, Schwarzler J, Tilg H
Ther Adv Endocrinol Metab
. 2022 Nov;
13:20420188221139101.
PMID: 36439029
Metabolic dysfunction-associated fatty liver disease (MAFLD) has appeared as the leading liver disease worldwide. Whereas the terminology nonalcoholic fatty liver disease (NAFLD) mainly reflected a negative selection and exclusion of...
10.
Adolph T, Meyer M, Schwarzler J, Mayr L, Grabherr F, Tilg H
Nat Rev Gastroenterol Hepatol
. 2022 Jul;
19(12):753-767.
PMID: 35906289
Crohn's disease and ulcerative colitis, phenotypically comprising a spectrum of inflammatory bowel diseases (IBDs), spread globally during the westernization of lifestyle and dietary habits over the past few decades. Here,...